Cytochrome P450 2D6 polymorphism and drug utilization in patients with oral lichen planus

Authors

  • Vladimíra Paulusová Department of Dentistry, Faculty of Medicine and University Hospital of Hradec Králové
  • Christiane Rösch Department of Pharmacology, 1st Faculty of Medicine and General Teaching Hospital
  • Ivo Dřízhal Department of Dentistry, Faculty of Medicine and University Hospital of Hradec Králové
  • František Perlík Department of Pharmacology, 1st Faculty of Medicine and General Teaching Hospital
  • Vladimír Mašín Department of Medical Biophysics, Faculty of Medicine of Hradec Králové, Charles University, Prague, Czech Republic
  • Sujith Sukumar Department of Dentistry, Faculty of Medicine and University Hospital of Hradec Králové
  • Radovan Slezák Department of Dentistry, Faculty of Medicine and University Hospital of Hradec Králové
  • Ondřej Slanař Department of Pharmacology, 1st Faculty of Medicine and General Teaching Hospital

DOI:

https://doi.org/10.3109/00016351003636382

Keywords:

CYP2D6, cytochrome P450, genetic polymorphism, oral lichen planus, pharmacotherapy

Abstract

Objective. Oral lichen planus (OLP) is one of the commonest diseases of the oral mucosa. The etiology of the disease is unknown. Our goal was to determine frequencies of functionally important alleles which determine the metabolic rate (phenotype) of individuals with OLP and to compare drug utilization, with focus on CYP2D6, with that of a control group. Material and methods. The study population consisted of 46 patients with OLP, 60 sex- and age-matched control subjects for drug utilization evaluation and 223 healthy non-medicated controls for genotype comparison. DNA analysis was done using polymerase chain reaction and restriction fragment length polymorphism. The gene CYP2D6 was analyzed for the alleles CYP2D6*3,*4,*5,*6 and gene duplication. Drug utilization was evaluated according to Anatomical Therapeutic Chemical code, liver drug metabolism pathway and mono- or polytherapy. Results. Intake of drugs was significantly higher in the group of OLP patients in comparison with control subjects. The use of CYP2D6 substrates, inhibitors or inducers did not differ between OLP patients and controls. Predicted phenotype frequencies in OLP patients and healthy controls, respectively were as follows: ultrarapid metabolizers 2% and 5.8%, extensive metabolizers 52% and 49.8%, intermediate metabolizers 39% and 37.7% and poor metabolizers 7% and 6.7%. Conclusions. We did not find a statistically significant difference in the frequency of CYP2D6 alleles between OLP patients and healthy controls. OLP patients used more medication than age- and sex-matched controls.

Downloads

Download data is not yet available.

Downloads

Published

2010-07-01